JP2012211164A5 - - Google Patents

Download PDF

Info

Publication number
JP2012211164A5
JP2012211164A5 JP2012138485A JP2012138485A JP2012211164A5 JP 2012211164 A5 JP2012211164 A5 JP 2012211164A5 JP 2012138485 A JP2012138485 A JP 2012138485A JP 2012138485 A JP2012138485 A JP 2012138485A JP 2012211164 A5 JP2012211164 A5 JP 2012211164A5
Authority
JP
Japan
Prior art keywords
val xaa
xaa pro
xau
isomer
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012138485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012211164A (ja
Filing date
Publication date
Priority claimed from US08/896,394 external-priority patent/US6143721A/en
Application filed filed Critical
Publication of JP2012211164A publication Critical patent/JP2012211164A/ja
Publication of JP2012211164A5 publication Critical patent/JP2012211164A5/ja
Pending legal-status Critical Current

Links

JP2012138485A 1997-07-18 2012-06-20 ドラスタチン15誘導体 Pending JP2012211164A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives
US08/896,394 1997-07-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008315263A Division JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体

Publications (2)

Publication Number Publication Date
JP2012211164A JP2012211164A (ja) 2012-11-01
JP2012211164A5 true JP2012211164A5 (cg-RX-API-DMAC7.html) 2013-01-10

Family

ID=25406130

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000503101A Expired - Fee Related JP4508413B2 (ja) 1997-07-18 1998-07-07 ドラスタチン15誘導体
JP2008315269A Expired - Fee Related JP5047935B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2008315263A Expired - Fee Related JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2012138485A Pending JP2012211164A (ja) 1997-07-18 2012-06-20 ドラスタチン15誘導体

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2000503101A Expired - Fee Related JP4508413B2 (ja) 1997-07-18 1998-07-07 ドラスタチン15誘導体
JP2008315269A Expired - Fee Related JP5047935B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2008315263A Expired - Fee Related JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体

Country Status (32)

Country Link
US (6) US6143721A (cg-RX-API-DMAC7.html)
EP (1) EP0991658B1 (cg-RX-API-DMAC7.html)
JP (4) JP4508413B2 (cg-RX-API-DMAC7.html)
KR (1) KR100579748B1 (cg-RX-API-DMAC7.html)
CN (1) CN1268636C (cg-RX-API-DMAC7.html)
AR (1) AR018501A1 (cg-RX-API-DMAC7.html)
AT (1) ATE314387T1 (cg-RX-API-DMAC7.html)
AU (1) AU750120B2 (cg-RX-API-DMAC7.html)
BG (1) BG65212B1 (cg-RX-API-DMAC7.html)
BR (1) BR9810911A (cg-RX-API-DMAC7.html)
CA (1) CA2296036C (cg-RX-API-DMAC7.html)
CO (1) CO4990967A1 (cg-RX-API-DMAC7.html)
CY (1) CY1107047T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303045B6 (cg-RX-API-DMAC7.html)
DE (1) DE69832982T2 (cg-RX-API-DMAC7.html)
DK (1) DK0991658T3 (cg-RX-API-DMAC7.html)
ES (1) ES2258819T3 (cg-RX-API-DMAC7.html)
HR (1) HRP980397A2 (cg-RX-API-DMAC7.html)
HU (1) HU228996B1 (cg-RX-API-DMAC7.html)
ID (1) ID24669A (cg-RX-API-DMAC7.html)
IL (1) IL133784A (cg-RX-API-DMAC7.html)
MY (1) MY135057A (cg-RX-API-DMAC7.html)
NO (1) NO326827B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ502296A (cg-RX-API-DMAC7.html)
PL (1) PL197884B1 (cg-RX-API-DMAC7.html)
PT (1) PT991658E (cg-RX-API-DMAC7.html)
RU (1) RU2195462C2 (cg-RX-API-DMAC7.html)
SK (1) SK286581B6 (cg-RX-API-DMAC7.html)
TR (2) TR200103545T2 (cg-RX-API-DMAC7.html)
TW (1) TW533217B (cg-RX-API-DMAC7.html)
WO (1) WO1999003879A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA986358B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6686336B2 (en) 2000-02-08 2004-02-03 Federal Government As Represented By The Department Of Veterans Affaires N-terminal D(-)-penicillamine peptides as aldehyde sequestration agents
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP5042444B2 (ja) 2002-03-22 2012-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌の処置におけるヘミアスタリン誘導体およびその利用法
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
EP2353611B1 (en) * 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
SG171682A1 (en) 2006-05-16 2011-06-29 Aegera Therapeutics Inc Iap bir domain binding compounds
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック, インコーポレイテッド 抗CD79b抗体及びイムノコンジュゲートとその使用方法
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
UA106586C2 (uk) 2008-01-31 2014-09-25 Дженентек, Інк. Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
NZ600608A (en) 2009-12-18 2015-01-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
EP3263583A1 (en) 2010-02-12 2018-01-03 Pharmascience Inc. Iap bir domain binding compounds
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
PT3122757T (pt) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Ligantes carregados e as suas utilizações em conjugação
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
NZ737471A (en) 2015-06-15 2022-02-25 Hangzhou Dac Biotech Co Ltd Hydrophilic linkers for conjugation
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2018086139A1 (en) 2016-11-14 2018-05-17 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 抗体の特異的共役

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
ES2144421T3 (es) * 1991-08-09 2000-06-16 Teikoku Hormone Mfg Co Ltd Nuevo derivado tetrapeptidico.
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
WO1993017388A1 (en) 1992-02-26 1993-09-02 Clark Paul C System for protecting computers via intelligent tokens or smart cards
JP3523253B2 (ja) * 1992-05-20 2004-04-26 アボット ゲーエムベーハー ウント カンパニー カーゲー ドラスタチン誘導体
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
DE69329425T2 (de) * 1992-12-16 2001-01-18 Basf Ag Dolastatin analog
US5554993A (en) 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
AU728161B2 (en) 1997-01-10 2001-01-04 Silicon Gaming, Inc. Method and apparatus using geoographical position and a universal time to determination means to provide authenticated, secure, on-line communication between remote gaming locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Similar Documents

Publication Publication Date Title
JP2012211164A5 (cg-RX-API-DMAC7.html)
JP2011511805A5 (cg-RX-API-DMAC7.html)
JP2011121989A5 (cg-RX-API-DMAC7.html)
JP2007269812A5 (cg-RX-API-DMAC7.html)
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
ES2603058T3 (es) Láminas, esponjas y bayetas revestidas de un tratamiento antimicrobiano
JP2013518057A5 (cg-RX-API-DMAC7.html)
JP2013542247A5 (cg-RX-API-DMAC7.html)
JP2009225798A5 (cg-RX-API-DMAC7.html)
JP2012512907A5 (cg-RX-API-DMAC7.html)
JP2012530060A5 (cg-RX-API-DMAC7.html)
NZ593524A (en) A nonapeptide with anti-tumour activity
JP2015024998A5 (cg-RX-API-DMAC7.html)
JP2015518055A5 (cg-RX-API-DMAC7.html)
JP2009535462A5 (cg-RX-API-DMAC7.html)
JP2008513467A5 (cg-RX-API-DMAC7.html)
JP2010065046A5 (cg-RX-API-DMAC7.html)
JP2013520405A5 (cg-RX-API-DMAC7.html)
EP2588099A4 (en) METHOD OF TREATING THE RESTLESS LEG SYNDROME
JP2009545527A5 (cg-RX-API-DMAC7.html)
JP2011137005A5 (cg-RX-API-DMAC7.html)
CL2008003322A1 (es) Compuestos derivados de acidos de ciclobutanoamino, moduladores de receptores s1p; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de artritis, enfermedades autoinmunes, diabetes tipo i, enfermedad pulmonar obstructiva cronica, entre otras.
JP2013503110A5 (cg-RX-API-DMAC7.html)
BR112012017691A2 (pt) nova composição
JP2010511631A5 (cg-RX-API-DMAC7.html)